

[Dihydroartemisinin + piperazine](#)

Statut de médicament essentiel

Section:

[6. Anti-infective medicines 6.5. Antiprotozoal medicines 6.5.3. Antimalarial medicines 6.5.3.1. Antimalarial medicines > Medicines for curative treatment](#)

Codes ATC: [P01BF05](#)

EMLc

Indication

Malaria due to Plasmodium vivax Code ICD11: [1F81](#)

Type de médicament

Chemical agent

Type de liste

Liste de base

Formulations

Oral > Solid > dispersible tablet: 20 mg + 160 mg (phosphate) (EMLc) ; 40 mg + 320 mg (phosphate) (EMLc)

Oral > Solid > tablet: 40 mg + 320 mg (phosphate) ; 20 mg + 160 mg (phosphate) ; 60 mg + 480 (phosphate) ; 80 mg + 640 mg (phosphate)

Historique des statuts LME

Ajouté pour la première fois en 2017 ([TRS 1006](#))

Modifié en 2025 ([TRS 1064](#))

Sexe

Tous

Âge

Aussi recommandé pour les enfants

Équivalence thérapeutique

La recommandation concerne ce médicament spécifique

Renseignements sur le brevet

Patents have expired in most jurisdictions

Lire la suite [sur les brevets.](#)

Wikipédia

[Dihydroartemisinin + piperazine](#)

DrugBank

[Artemimol](#),

[Piperaquine](#)

Résumé des preuves et recommandation du comité d'experts



Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of two new strengths of tablets (60mg + 480 mg and 80 mg + 840 mg) on the EML and EMLc; - the addition of two new strengths of dispersible tablets (20 mg + 160 mg and 40 mg + 320 mg) on the EMLc; - removal of the weight restriction, in recognition that use should be in line with recommendations with WHO guidelines; - to update the listing to include reference to the phosphate salt of piperazine in the formulation description instead of the medicine name.